Integrative CRISPR-Cas9 dependency analysis identifies CDC45 as a candidate prognostic biomarker with preliminary functional validation in prostate adenocarcinoma

Xie, Yuxin, Wang, Shuo, Gao, Yukui
Journal of Molecular Histology · Springer Nature · 2026-11-13 · DOI: 10.1007/s10735-026-11010-y

Abstract

Prostate adenocarcinoma (PRAD) has become one of the most prevalent malignancies in men worldwide. Although advances in diagnostic techniques and targeted therapies have improved clinical outcomes, a significant subset of patients still develops aggressive, metastatic disease with limited treatment options. At present, identifying reliable biomarkers for early risk stratification remains a critical unmet need in prostate cancer research. This study presents a dependency-informed prognostic prioritization approach by integrating multi-omics data to enhance clinical risk stratification in prostate adenocarcinoma (PRAD). Integrated analysis of CRISPR-Cas9 dependency screens and bulk RNA sequencing data prioritized tumor-dependent genes associated with PRAD cell viability. Pathway enrichment analysis indicated the involvement of these candidate genes in cell cycle regulation and tumor progression. Subsequently, an 11-gene prognostic signature was constructed via LASSO regression, effectively stratifying patients, with the high-risk cohort demonstrating significantly reduced Progression-Free Interval (PFI; log-rank p < 0.001). Among the prioritized hub genes, CDC45 exhibited marked upregulation in tumor tissues, which was confirmed by Western blotting and qRT-PCR. Collectively, this study provides a dependency-informed prognostic framework for PRAD and nominates CDC45 as a candidate prognostic biomarker, laying the groundwork for future mechanistically resolved investigations.

Read at publisher →

Similar articles